Patent: 10,406,213
✉ Email this page to a colleague
Summary for Patent: 10,406,213
Title: | Injection paradigm for administration of botulinum toxins |
Abstract: | Methods for treating a patient suffering from a medication overuse headache disorder are provided. The methods comprise administering to a patient suffering from a medication overuse disorder a Clostridial toxin. The toxin is administered to the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient. |
Inventor(s): | Turkel; Catherine C. (Newport Coast, CA), Aurora; Sheena K. (Seattle, WA), Brin; Mitchell F. (Newport Beach, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Application Number: | 15/707,452 |
Patent Claims: | see list of patent claims |
Details for Patent 10,406,213
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | BOTOX COSMETIC | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 10,406,213 | 2030-03-30 |
Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 10,406,213 | 2030-03-30 |
Ipsen Biopharm Limited | DYSPORT | abobotulinumtoxina | For Injection | 125274 | April 29, 2009 | 10,406,213 | 2030-03-30 |
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc | XEOMIN | incobotulinumtoxina | For Injection | 125360 | July 30, 2010 | 10,406,213 | 2030-03-30 |
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc | XEOMIN | incobotulinumtoxina | For Injection | 125360 | November 20, 2015 | 10,406,213 | 2030-03-30 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |